Drug Search Results
More Filters [+]

Cladribine

Alternative Names: cladribine, 2-chlorodeoxyadenosine, 2-cda, chlorodeoxyadenosine, mavenclad, leustatin
Latest Update: 2024-12-10
Latest Update Note: Clinical Trial Update

Product Description

Cladribine is used to treat hairy cell leukemia (cancer of a certain type of white blood cell). Cladribine is in a class of medications known as purine analogs. It works by stopping or slowing the growth of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a693015.html)

Mechanisms of Action: TK Inhibitor,ADA Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela

Approved Indications: Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

Known Adverse Events: Headache | Lymphopenia | Respiratory Tract Infections

Company: Merck KGaA
Company Location: GERMANY HRB 6164 I8
Company CEO: Belen Garijo
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cladribine

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Czech Republic, Denmark, France, Georgia, Germany, Greece, Ireland, Italy, Japan, Korea, Netherlands, Norway, Poland, Spain, Sweden, Taiwan, United Kingdom, United States

Active Clinical Trial Count: 12

Highest Development Phases

Phase 3: Histiocytosis|Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis, Relapsing-Remitting|Muscle Weakness|Myasthenia Gravis

Phase 2: Acute Monocytic Leukemia|Acute Myeloid Leukemia|Biphenotypic Acute Leukemia|Myelodysplastic Syndrome|Myeloproliferative Disorders|Preleukemia

Phase 1: Multiple Sclerosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MS700568_0183

P3

Unknown Status

Myasthenia Gravis

2031-02-28

jRCT2031240175

P3

Not yet recruiting

Myasthenia Gravis

2031-02-28

MyClad

P3

Recruiting

Muscle Weakness|Myasthenia Gravis

2028-05-19

MCC-23154

P2

Not yet recruiting

Acute Myeloid Leukemia

2027-11-01

Recent News Events